Clinical Trial Update: A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy [Phase 2]

View source ↗

Summary

This update reports results from a Phase 2 single-agent trial of regorafenib in patients with advanced or metastatic biliary tract carcinoma/cholangiocarcinoma …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer
• Cholangiocarcinoma

Drugs mentioned

• Stivarga (regorafenib)

Snippet

Sponsor: Nathan Bahary, MD | Conditions: Metastatic Biliary Tract Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2019-01-30